MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Organon & Co. Common Stock (NY:OGN)

13.55 UNCHANGED
Official Closing Price Updated: 7:00 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Organon & Co. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
Organon To Report First Quarter 2026 Results and Host Conference Call on May 7, 2026
From Organon & Co.
Via Business Wire
News headline image
Organon’s VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis
From Organon & Co.
Via Business Wire
Organon & Co (NYSE:OGN) Shares Drop on Q4 Earnings Miss and Flat 2026 Outlook ↗
Via Chartmill
Topics Earnings
News headline image
3 Reasons to Avoid OGN and 1 Stock to Buy Instead
Over the last six months, Organon’s shares have sunk to $9.03, producing a disappointing 5.9% loss - a stark contrast to the S&P 500’s 2.5% gain. This may ha... 
Via StockStory
Topics Stocks
News headline image
Traders are paying attention to the gapping stocks in Friday's session. ↗
Let's delve into the US markets on Friday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
Topics Artificial Intelligence
News headline image
Discover the top movers in Friday's pre-market session. ↗
Wondering what's happening in Friday's pre-market session? Find an overview in this article. 
Via Chartmill
News headline image
Guardant Health, Organon, Fortrea, QuidelOrtho, and Charles River Laboratories Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after a proposed 2027 federal budget revealed significant spending cuts for key health agenci... 
Via StockStory
Topics Government Stocks
News headline image
Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age
From Organon & Co.
Via Business Wire
News headline image
3 Cash-Producing Stocks We’re Skeptical Of
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Cas... 
Via StockStory
Topics Fraud
News headline image
Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6? ↗
Organon & Co. develops branded and biosimilar therapies with a focus on women’s health and specialty pharmaceuticals. 
Via The Motley Fool
News headline image
3 Value Stocks We Approach with Caution
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the... 
Via StockStory
News headline image
1 Stock Under $10 to Own for Decades and 2 That Underwhelm
Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums). That doesn’t mean they’re barga... 
Via StockStory
News headline image
3 of Wall Street’s Favorite Stocks We Approach with Caution
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic... 
Via StockStory
News headline image
3 Small-Cap Stocks We Approach with Caution
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and... 
Via StockStory
News headline image
New Analysis of Organon’s VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis
From Organon & Co.
Via Business Wire
News headline image
The Pivot to Growth: Viatris (VTRS) Enters Phase 2 with 2026 Dividend and Capital Allocation Strategy
As of February 26, 2026, Viatris Inc. (NASDAQ: VTRS) finds itself at a defining crossroads. For years, the company was viewed by many on Wall Street as a "value trap"—a debt-laden giant formed from the... 
Via Finterra
Topics Economy
News headline image
Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device
From Organon & Co.
Via Business Wire
News headline image
5 Revealing Analyst Questions From Organon’s Q4 Earnings Call
Organon's fourth quarter was met with a negative market reaction as operational challenges and shifting demand patterns weighed on results. Management pointed to continued pricing pressure, loss of... 
Via StockStory
Topics Earnings
News headline image
Amphastar Pharmaceuticals, Novavax, and Organon Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after a softer-than-expected inflation report fueled hopes for interest rate cuts by the Federal Reserve. The January Consumer Price Index (CPI), a... 
Via StockStory
Topics Economy
News headline image
OGN Q4 Deep Dive: Margin Compression and U.S. Headwinds Shape 2026 Outlook
Pharmaceutical company Organon (NYSE:OGN) met Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 5.3% year on year to $1.51 billion. The company’s full-year revenue guidance of $6.2... 
Via StockStory
News headline image
Organon (OGN) Q4 2025 Earnings Call Transcript ↗
Organon (OGN) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Organon (NYSE:OGN) Reports Q4 CY2025 In Line With Expectations
Pharmaceutical company Organon (NYSE:OGN) met Wall Street’s revenue expectations in Q4 CY2025, but sales fell by 5.3% year on year to $1.51 billion. The company’s full-year revenue guidance of $6.2... 
Via StockStory
News headline image
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025
From Organon & Co.
Via Business Wire
News headline image
Organon Earnings: What To Look For From OGN
Pharmaceutical company Organon (NYSE:OGN) will be announcing earnings results this Thursday morning. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence World Trade
News headline image
2 Healthcare Stocks with Promising Prospects and 1 We Brush Off
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but... 
Via StockStory
Topics Stocks
News headline image
Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026
From Organon & Co.
Via Business Wire
News headline image
Organon Completes Divestiture of JADA® System to Laborie
From Organon & Co.
Via Business Wire
News headline image
The Post-Keytruda Pivot: Inside Merck’s Strategic Evolution and the RVMD Landscape
As of January 26, 2026, Merck & Co. (NYSE: MRK) stands at the most critical juncture in its 135-year history. Known globally for its dominant oncology franchise and robust vaccine portfolio, the... 
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story